Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2018
At a glance
- Drugs Irinotecan (Primary) ; Irinotecan (Primary) ; Pazopanib (Primary) ; Temozolomide (Primary)
- Indications Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms PAZIT
- 05 Jun 2018 Study design was presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 29 Aug 2017 Status changed from not yet recruiting to recruiting.
- 05 May 2017 New trial record